Human Papillomavirus Minor Capsid Protein L2 (L2) - Pipeline Review, H2 2017

November 2017 | 30 pages | ID: H686E68E78EEN
Global Markets Direct

Abstracts

Human Papillomavirus Minor Capsid Protein L2 (L2) - Pipeline Review, H2 2017

SUMMARY

Human Papillomavirus Minor Capsid Protein L2 (L2) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Human Papillomavirus Minor Capsid Protein L2 (L2) - Pipeline Review, H2 2017, outlays comprehensive information on the Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Human Papillomavirus Minor Capsid Protein L2 (L2) - L2 is a minor capsid component and lacks the capacity to form VLPs. This protein plays a role in capsid stabilization through interaction with the major capsid protein L1. It also plays a role through its interaction with host dyne in in the intracellular microtubule-dependent transport of viral capsid toward the nucleus. It mediates the viral genome import into the nucleus through binding to host importins. The molecules developed by companies in Preclinical stages are 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Cervical Cancer, Human Papillomavirus (HPV) Associated Cancer, Human Papillomavirus Infections, Genital Warts (Condylomata Acuminata) and Warts.

Furthermore, this report also reviews key players involved in Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Minor Capsid Protein L2 (L2)
• The report reviews Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics and enlists all their major and minor projects
• The report assesses Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Human Papillomavirus Minor Capsid Protein L2 (L2)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Human Papillomavirus Minor Capsid Protein L2 (L2) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Human Papillomavirus Minor Capsid Protein L2 (L2) - Overview
Human Papillomavirus Minor Capsid Protein L2 (L2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Human Papillomavirus Minor Capsid Protein L2 (L2) - Therapeutics Assessment
Assessment by Route of Administration
Assessment by Molecule Type
Human Papillomavirus Minor Capsid Protein L2 (L2) - Companies Involved in Therapeutics Development
Agilvax Inc
Cancer Research Technology Ltd
Pathovax LLC
Human Papillomavirus Minor Capsid Protein L2 (L2) - Drug Profiles
AX-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PVX-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RGVax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TA-CIN - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target HPV Minor Capsid Protein L2 for Cervical Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Human Papillomavirus Minor Capsid Protein L2 (L2) - Dormant Products
Human Papillomavirus Minor Capsid Protein L2 (L2) - Product Development Milestones
Featured News & Press Releases
Oct 27, 2016: PathoVax Wins $500,000 in 43North Contest
Sep 06, 2016: Agilvax Receives New Patent for Its Cost-Effective Broadly Protective HPV Vaccine Candidate
Feb 03, 2015: Agilvax Is Advancing Clinical Production of its Lead Vaccine Against Human Papillomavirus
Oct 30, 2014: National Cancer Institute supports next-generation Austrian HPV vaccine
Sep 10, 2013: New, Even More Effective HPV Vaccine In Sight
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Agilvax Inc, H2 2017
Pipeline by Cancer Research Technology Ltd, H2 2017
Pipeline by Pathovax LLC, H2 2017
Dormant Projects, H2 2017

List Of Figures

LIST OF FIGURES

Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

Agilvax Inc
Cancer Research Technology Ltd
Pathovax LLC